Brodalumab could be effective treatment for nail, scalp psoriasis

| Melissa Leavitt

A new psoriasis drug that’s already showed promising results as a whole-body treatment in clinical trials can help clear hard-to-treat areas, too.

According to a Japanese study, certain doses of brodalumab can be an effective therapy for nail and scalp psoriasis. The study, which was presented at the European Academy of Dermatology and Venereology meeting in October 2014, involved 145 Japanese patients. Among this group, 137 had scalp psoriasis, and 89 had nail psoriasis.

Brodalumab, which is being developed by Amgen, targets interleukin-17 (IL-17), a cytokine, or protein, involved in the inflammatory process of psoriasis.

In the Japanese study, patients were randomly assigned to take one of three doses of brodalumab, or a placebo.

Three months of treatment with the two highest doses of brodalumab resulted in dramatic clearing of the scalp. These doses also improved nail psoriasis, but did not deliver the same degree of clearance.

Patients with nail psoriasis taking the highest dose of the drug, 210 milligrams (mg), experienced an average of 47.3 percent improvement. Patients taking the next-highest dose, 140 mg, experienced an average of 44.9 percent improvement. Patients taking the placebo experienced an average of 9.6 percent improvement.

Nail improvement was evaluated using the Nail Psoriasis Severity Index (NAPSI), which measures symptoms such as nail pitting and discoloration.

Brodalumab delivered stronger improvement for scalp psoriasis. Using the Psoriasis Scalp Severity Index (PSSI), which measures symptoms such as redness and peeling, patients on the 210 mg dose improved an average of 94.5 percent, while patients on the 140 mg dose improved an average of 73.8 percent, according to the data. Patients taking the placebo improved by 12.6 percent.

At the European meeting, Amgen also presented data at the European meeting from a long-term trial that showed that more than half of the patients in the trial had completely clear skin after more than two-and-a-half years of treatment. 

Brodalumab also has had encouraging results as a treatment for psoriatic arthritis (PsA). Almost two-thirds of PsA patients enrolled in a Phase II trial of trial of the drug experienced a 20 percent improvement in their symptoms.

A Phase III trial testing brodalumab as a psoriasis treatment is ongoing, and a Phase III trial for psoriatic arthritis is currently recruiting.

Other drugs targeting IL-17 currently in development include secukinumab and ixekizumab.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Never mind an endless series of debates. Meet Matt Mercier, one of our three...
PPI
NPF has embarked on the Psoriasis Prevention Initiative– a multi-disciplinary,...
Tami Seretti is one of three individuals who have distinguished themselves with...
The 2019 NPF annual survey is your opportunity to share your data and help...
Facebook fundraiser
It’s easy to start supporting NPF research with your own personal fundraising...
Data collection alone won't find us a cure for psoriatic disease. First we...
The best treatment starts with a team of medical professionals who are up-to-...
NPF board of directors member Richard Seiden shares his notes.
Kory Schrom, M.D.
Researcher Kory Schrom’s interest in the microbiome may answer this and other...